Cover Image

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China

Abstract Background Niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for first/second-line maintenance treatment of ovarian cancer patients with complete or partial response to platinum-based chemotherapy, and multi-line monotherapy in BRCAmt patients or platinum-sensitive rec...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jing Ni (Author), Xianzhong Cheng (Author), Qian Zhao (Author), Zhiqin Dai (Author), Xia Xu (Author), Wenwen Guo (Author), Hongyuan Gu (Author), Rui Zhou (Author), Yan Wang (Author), Xiaoxiang Chen (Author)
Format:	Book
Published:	BMC, 2021-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China
by: Jing Ni, et al.
Published: (2019)

Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
by: Jing Ni, et al.
Published: (2020)

The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial
by: Hongyuan Gu, et al.
Published: (2020)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
by: Mauro Francesco Pio Maiorano, et al.
Published: (2023)

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
by: Yin Shi, et al.
Published: (2023)

A case of niraparib PARP-Inhibitor induced Sweet Syndrome in gynecologic cancer
by: Nora Badiner, et al.
Published: (2023)

Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
by: Jing Nie, et al.
Published: (2023)

Genomic alteration discordance in the paired primary-recurrent ovarian cancers: based on the comprehensive genomic profiling (CGP) analysis
by: Jiayin Dong, et al.
Published: (2024)

Challenges in PARP inhibitor therapy: A case of Olaparib-induced liver injury and successful rechallenge with Niraparib
by: Kai Zhu, et al.
Published: (2024)

Age is associated with prognosis in serous ovarian carcinoma
by: Fei Deng, et al.
Published: (2017)

Niraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report
by: Xiaolong Yue, et al.
Published: (2024)

Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China
by: Kaituo Huang, et al.
Published: (2023)

The safety and feasibility of no-placement of urinary catheter after single-port laparoscopic surgery in patients with benign ovarian tumor: A retrospective cohort study
by: Jing Deng, et al.
Published: (2023)

Case Report: Complete Remission of C1q Nephropathy Treated With a Single Low-Dose Rituximab, a Reality or Coincidence?
by: Rui Ma, et al.
Published: (2021)

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
by: Giovanni Canil, et al.
Published: (2023)

Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective, observational study
by: Li Li, et al.
Published: (2020)

Clinical outcomes and safety of anakinra in the treatment of multisystem inflammatory syndrome in children: a single center observational study
by: Brian L.P. Dizon, et al.
Published: (2023)

Anticoagulation Quality of Warfarin and the Role of Physician-Pharmacist Collaborative Clinics in the Treatment of Patients Receiving Warfarin: A Retrospective, Observational, Single-Center Study
by: Sha Qiu, et al.
Published: (2021)

Abnormalities in microbial composition and function in infants with necrotizing enterocolitis: A single-center observational study
by: Huan Huang, et al.
Published: (2022)

Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study
by: Ayman M. Al-Qaaneh, et al.
Published: (2022)

Short-Term Efficacy of Tenofovir Alafenamide in Acute-On-Chronic Liver Failure: A Single Center Experience
by: Zhiqin Li, et al.
Published: (2024)

The effect of albumin and hemoglobin levels on the prognosis of early-stage cervical cancer: a prospective, single-center-based cohort study
by: Xinmei Wang, et al.
Published: (2023)

CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery
by: Wang Fang, et al.
Published: (2013)

Spotlight on eltrombopag concentration in pediatric immune thrombocytopenia: A single‐center observational study in China
by: Shuyue Dong, et al.
Published: (2024)

Spongiotic Pattern in Pemphigus: A Retrospective Observational Single-Center Study
by: Ivan Arni C. Preclaro, et al.
Published: (2022)

Left Atrium Involvement in Lymphoma Patients: Single Center Observational Study
by: E. Yu. Salakheeva, et al.
Published: (2022)

Catheters linked thrombosis in neonates: a single center observational study
by: Marwa Mohamed Farag, et al.
Published: (2024)

Dysproteinemia-Associated Kidney Disease: A Single-Center Observational Study
by: João Bernardo, et al.
Published: (2022)

Vitrification freezing of large ovarian tissue in the human body
by: Qian Zhao, et al.
Published: (2019)

Ovarian fibrosarcoma: A single-institution experience and a review of the literature
by: Ting-Ting Sun, et al.
Published: (2020)

Impact of Adverse Events Associated With Acitretin Treatment of Moderate-to-Severe Plaque Psoriasis: Based on an Observational, Single-Center Study in Shanghai, China
by: Xiao-Yuan Zhong, et al.
Published: (2023)

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
by: Xin-Ru Li, et al.
Published: (2022)

Efficacy and safety of Shen Que (RN8) moxibustion on reproductive outcomes in unexpected poor ovarian responders: a randomized controlled trial
by: Jing-Yan Song, et al.
Published: (2024)

Clinical Features and Management of Women with Borderline Ovarian Tumors in a Single Center in Brazil
by: Adriana Yoshida, et al.
Published: (2019)

Restrictive Fluid Therapy for High-Complexity Advanced Ovarian Cancer Surgery: A Single-Center Retrospective Cohort Study
by: Qin-Feng Zhang, et al.
Published: (2023)

Efficacy and safety of carotid artery stenting: Experience of a single center
by: Bilge Duran Karaduman, et al.
Published: (2020)

Impact of ultrasound-guided high-intensity focused ultrasound for the treatment of uterine fibroids on ovarian reserve and quality of life: a single-center prospective cohort study
by: Wei Gu, et al.
Published: (2024)

Integrated analysis of single-cell RNA-seq and bulk RNA-seq unveils heterogeneity and establishes a novel signature for prognosis and tumor immune microenvironment in ovarian cancer
by: Zitao Wang, et al.
Published: (2023)

Management of Borderline ovarian tumors (BOT): results of a retrospective, single center study in Switzerland
by: B. Kipp, et al.
Published: (2023)

Oligogenic basis of premature ovarian insufficiency: an observational study
by: Panpan Long, et al.
Published: (2024)